This article was organised and fully funded by Bristol Myers Squibb, as a follow-up to a roundtable hosted in collaboration with HSJ. This article has been developed by HSJ and Bristol Myers Squibb has reviewed the article to check for accuracy. This article has no promotional intent. Bristol Myers Squibb does not intend to encourage the use of, or advocate the promotion of, its products through the objectives of this article.

Read the detailed report here.

Sponsored byBMS logo@2x-8

Treatments for cancer are rapidly evolving, potentially offering better outcomes. Quickly transferring breakthroughs into clinical practice remains challenging, however. In this respect, innovation in cancer is similar to innovations more broadly in the NHS. Often there are questions about how best to quickly implement new ways of doing things uniformly across an organisation – and indeed beyond, across the service.

So what do emerging treatments for cancer tell us about how the NHS can best adopt and spread innovation? That was the topic on the agenda for a recent HSJ  roundtable held in association with Bristol Myers Squibb. It brought together a small panel of experts, who identified important ingredients for successful innovation in healthcare: among them, clinician involvement, patient involvement, and better means of communication.


  • Dany Bell, strategic adviser treatment, new personalised medicine and genomics, Macmillan Cancer Support
  • Pinkie Chambers, lead pharmacist applied health research, University College London Hospitals Foundation Trust and chair of chemotherapy expert reference group, North Central London Cancer Alliance
  • Jagtar Dhanda, policy, advocacy and government affairs manager, BMS
  • Ricky Frazer, consultant oncologist in acute oncology, melanoma and renal cancer, Velindre Cancer Centre
  • Ceinwen Giles, chair, NHS England Cancer Programme Patient and Public Voices Forum and founding director, Shine Cancer Support
  • Trudy Guinan, immunotherapy lead nurse, The Clatterbridge Cancer Centre Foundation Trust
  • Anna Olsson-Brown, medical oncology specialist registrar, The Clatterbridge Cancer Centre Foundation Trust and Medical Research Council clinical research fellow, University of Liverpool


Document number: ONC-GB-2100868

Date of preparation: 09.11.21